 Sovodak 60/400 | |
| Combination of | |
|---|---|
| Daclatasvir | NS5A inhibitor |
| Sofosbuvir | NS5B (RNA polymerase) inhibitor |
| Clinical data | |
| Trade names | Darvoni,[1] Sovodak |
| Routes of administration | Oral |
| Identifiers | |
| CAS Number | |
Daclatasvir/sofosbuvir (trade names Darvoni, Sovodak) is a two-drug combination for the treatment of hepatitis C.[2] It is given as a single daily pill containing daclatasvir, a viral NS5A inhibitor,[3] and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase NS5B.[4]
It is on the World Health Organization's List of Essential Medicines.[5]
- ^ "Home". Darvoni - Beacon Medicare Limited.
- ^ Pol S, Corouge M, Vallet-Pichard A (2016). "Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life". Hepatic Medicine: Evidence and Research. 8: 21–26. doi:10.2147/HMER.S62014. PMC 4786064. PMID 27019602.
- ^ "Daklinza film-coated tablets – Summary of Product Characteristics (SPC) - (eMC)". Electronic Medicines Compendium. September 2016. Archived from the original on 2016-11-09.
- ^ "Sovaldi 400 mg film coated tablets - Summary of Product Characteristics". UK Electronic Medicines Compendium. September 2016. Archived from the original on 10 November 2016. Retrieved 10 November 2016.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.